| Project/Area Number |
17590796
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
YANAGIHARA K. Nagasaki University, Laboratory Medicine University Hospital, lecturer, 医学部・歯学部附属病院, 講師 (40315239)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOHNO S. Nagasaki University, Graduate School of Medical Science, professor, 大学院医歯薬学総合研究科, 教授 (80136647)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 2006: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 2005: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | respiratory infection / gene therapy / SiRNA / pathogenesis / pneumococcus / Pseudomonas aeruginosa / MRSA |
|---|
| Research Abstract |
The anti-PcrV IgG reduced excessive inflammatory reactions, such as the recruitment of inflammatory cells and the production of pro-inflammatory cytokines, caused by chronic P.aeruginosa respiratory infection. These data suggest that treatment with anti-PcrV IgG may be useful in chronic P.aeruginosa respiratory infection. (Imamura Y, Yanagihara K, et al. Eur.Respir.J. 2007 in press)
Telithromycin reduced the number of viable bacteria by inhibiting biofilm formation in the absence of an anti-inflammatory effect. The present data also indicated a difference between the effects of macrolides and ketolides against chronic respiratory infections. (Yanagihara K, et al. Chemotherapy 2007;53:10-13)
Sivelestat prolonged survival in a severe pneumococcal pneumonia model. A possible explanation for the improved survival is that sivelestat prevents tissue damage by inhibiting NE activity in the lung. As a result of this reduced damage, the number of viable bacteria recovered from blood is lower in the sivelestat group than in the control group. Thus, improved mortality rates were seen with sivelestat treatment. NE inhibitors may therefore be useful in treating with patients with severe pneumonia. (Yanagihara K, et al. Experimental Lung Research, Mar;33(2):71-80)
|
